Fig 1: CATED promoted the stability of DHX36 through SUMOylation. a) Correlation coefficient analysis of CATED and DHX36 expression was conducted, with the Pearson correlation coefficient (R) and p‐value (p) reported. b) DHX36 protein levels were assessed by Western blot analysis in CATED overexpression and knockdown cells. c,d) CHX assay of DHX36 protein stability. CATED‐overexpressing cells were treated with CHX (100 µg mL−1) and harvested at specified time points for Western blot analysis. The band intensity of DHX36 was quantified from three independent replicates, with the intensity at 0 h normalized to 1. CHX, Cycloheximide. e) Co‐IP assay utilizing anti‐DHX36 was conducted to evaluate the conjunction of SUMO2 on DHX36 in SKOV3 and COV504 cells. f) Co‐IP assay using anti‐FLAG was performed to assess the conjunction of FLAG‐labeled SUMO2 on DHX36 in cells. g) DHX36 protein levels were assessed by Western blot analysis in CATED overexpression alone or with ML‐792 (MCE, HY‐108702). h) Co‐IP assay using anti‐DHX36 was performed to assess the conjunction of SUMO2 on DHX36 in cells after CATED overexpression. S‐DHX36: SUMOylated DHX36. i) WT and mutants of DHX36 with His‐SUMO2 were transfected into SKOV3 cells as indicated. SUMO2 conjugated DHX36 proteins were immunoblotted. K, lysine; R, arginine; WT, wild type. j,k) CHX assay of FLAG‐tagged DHX36 protein and its mutant stability upon CATED‐overexpressing in SKOV3 and COV504 cells. CHX, Cycloheximide. p values were determined with ANOVA test. *p < 0.05, **p < 0.01. All data were from three repeats.